| scholarly article | Q13442814 |
| P356 | DOI | 10.4155/FMC-2017-0008 |
| P698 | PubMed publication ID | 28394627 |
| P50 | author | Sotirios Katsamakas | Q56934228 |
| Vasiliki Sarli | Q80512178 | ||
| P2093 | author name string | Savvas Thysiadis | |
| Theodora Chatzisideri | |||
| P2860 | cites work | Cooperation between integrin alphavbeta3 and VEGFR2 in angiogenesis | Q24318607 |
| Tumor-selective response to antibody-mediated targeting of alphavbeta3 integrin in ovarian cancer | Q24650026 | ||
| Tubulin-interactive natural products as anticancer agents | Q24650163 | ||
| Prodrug Strategies for Paclitaxel | Q26745997 | ||
| Small-molecule SMAC mimetics as new cancer therapeutics | Q26864204 | ||
| Tumor angiogenesis: therapeutic implications | Q27860595 | ||
| The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs | Q28066801 | ||
| Current status and future prospects for satraplatin, an oral platinum analogue | Q28272920 | ||
| New perspectives in cell adhesion: RGD and integrins | Q28280381 | ||
| Integrins in cancer: biological implications and therapeutic opportunities | Q29614536 | ||
| Cell attachment activity of fibronectin can be duplicated by small synthetic fragments of the molecule | Q29616413 | ||
| Angiogenesis as a therapeutic target | Q29619525 | ||
| IAP proteins: blocking the road to death's door | Q29619844 | ||
| Tumor necrosis is associated with increased alphavbeta3 integrin expression and poor prognosis in nodular cutaneous melanomas | Q33390467 | ||
| Dual targeting of integrin αvβ3 and matrix metalloproteinase-2 for optical imaging of tumors and chemotherapeutic delivery | Q33732724 | ||
| The synthesis of a c(RGDyK) targeted SN38 prodrug with an indolequinone structure for bioreductive drug release | Q33775446 | ||
| Characterization of a designed vascular endothelial growth factor receptor antagonist helical peptide with antiangiogenic activity in vivo | Q33807409 | ||
| Ligand binding to integrins | Q33912940 | ||
| A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer | Q34106382 | ||
| Integrin activation controls metastasis in human breast cancer | Q34107054 | ||
| How Taxol/paclitaxel kills cancer cells. | Q34166802 | ||
| Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia | Q34235776 | ||
| Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems. | Q34320295 | ||
| Synthesis and biological evaluation (in vitro and in vivo) of cyclic arginine-glycine-aspartate (RGD) peptidomimetic-paclitaxel conjugates targeting integrin αVβ3. | Q34472456 | ||
| The cryptophycins: their synthesis and anticancer activity | Q34540048 | ||
| Mechanisms of normal and tumor-derived angiogenesis | Q34592513 | ||
| The resurgence of platinum-based cancer chemotherapy | Q34649255 | ||
| Glucocorticosteroids: current and future directions | Q34903070 | ||
| Integrin targeting for tumor optical imaging | Q34912662 | ||
| Mechanisms involved in the side effects of glucocorticoids | Q35003894 | ||
| Tumor-specific expression of alphavbeta3 integrin promotes spontaneous metastasis of breast cancer to bone. | Q35012766 | ||
| Doxorubicin pathways: pharmacodynamics and adverse effects | Q35048393 | ||
| Cilengitide: the first anti-angiogenic small molecule drug candidate design, synthesis and clinical evaluation | Q35701298 | ||
| Targeting the mitogen-activated protein kinase cascade to treat cancer | Q35968411 | ||
| Topoisomerase I interaction with SV40 DNA in the presence and absence of camptothecin | Q36077065 | ||
| Anthracycline-induced cardiotoxicity in children with cancer: strategies for prevention and management | Q36116430 | ||
| Recent advances in tumor-targeting anticancer drug conjugates. | Q36162882 | ||
| Synthesis, Characterization, and Biological Evaluation of a Dual-Action Ligand Targeting αvβ3 Integrin and VEGF Receptors | Q36170277 | ||
| RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumour vasculature | Q36323144 | ||
| Taxol stabilizes microtubules in mouse fibroblast cells | Q36360499 | ||
| Integrins in cancer treatment | Q36418046 | ||
| Correlation between the tumoral expression of beta3-integrin and outcome in cervical cancer patients who had undergone radiotherapy | Q36615716 | ||
| Pharmaceutical and physical properties of paclitaxel (Taxol) complexes with cyclodextrins | Q36819106 | ||
| Conjugated platinum(IV)-peptide complexes for targeting angiogenic tumor vasculature | Q36826103 | ||
| Basis for design and development of platinum(IV) anticancer complexes | Q36865704 | ||
| Endocytic mechanisms for targeted drug delivery | Q36894849 | ||
| Integrin trafficking and its role in cancer metastasis | Q36929556 | ||
| Cancer therapies utilizing the camptothecins: a review of the in vivo literature | Q37069556 | ||
| Effect of N-methyl deuteration on metabolism and pharmacokinetics of enzalutamide | Q37082790 | ||
| The functions and applications of RGD in tumor therapy and tissue engineering | Q37091818 | ||
| Integrins in angiogenesis and lymphangiogenesis | Q37170752 | ||
| Prostate cancer specific integrin alphavbeta3 modulates bone metastatic growth and tissue remodeling | Q37365541 | ||
| The functional role of cell adhesion molecules in tumor angiogenesis. | Q37501507 | ||
| Function and antagonism of beta3 integrins in the development of cancer therapy. | Q37515522 | ||
| Small molecule integrin antagonists in cancer therapy | Q37636249 | ||
| Targeting alphavbeta3 integrin: design and applications of mono- and multifunctional RGD-based peptides and semipeptides | Q37694643 | ||
| Aggregation-induced emission | Q37907889 | ||
| Doxorubicin (adriamycin): a critical review of free radical-dependent mechanisms of cytotoxicity | Q37949829 | ||
| Radiolabelled RGD peptides for imaging and therapy | Q37990409 | ||
| Tumor Targeting via Integrin Ligands | Q38134759 | ||
| Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities | Q38244395 | ||
| αvβ3 Integrin-Targeted Peptide/Peptidomimetic-Drug Conjugates: In-Depth Analysis of the Linker Technology | Q38540942 | ||
| Targeted Drug Delivery System for Platinum-based Anticancer Drugs | Q38639391 | ||
| Synthesis, biological studies and molecular dynamics of new anticancer RGD-based peptide conjugates for targeted drug delivery | Q38807657 | ||
| Design, synthesis and biological evaluation of novel dimeric and tetrameric cRGD-paclitaxel conjugates for integrin-assisted drug delivery | Q38864088 | ||
| An integrin-targeted photoactivatable Pt(IV) complex as a selective anticancer pro-drug: synthesis and photoactivation studies | Q38878464 | ||
| A platinum prodrug conjugated with a photosensitizer with aggregation-induced emission (AIE) characteristics for drug activation monitoring and combinatorial photodynamic-chemotherapy against cisplatin resistant cancer cells. | Q38883923 | ||
| Synthesis and biological evaluation of RGD peptidomimetic-paclitaxel conjugates bearing lysosomally cleavable linkers | Q38898249 | ||
| Integrin-targeted delivery into cancer cells of a Pt(IV) pro-drug through conjugation to RGD-containing peptides | Q38942848 | ||
| Targeted theranostic prodrugs based on an aggregation-induced emission (AIE) luminogen for real-time dual-drug tracking | Q38964655 | ||
| Synthesis and biological evaluation of dual action cyclo-RGD/SMAC mimetic conjugates targeting α(v)β(3)/α(v)β(5) integrins and IAP proteins. | Q39003639 | ||
| Synthesis and biological evaluation of RGD-conjugated MEK1/2 kinase inhibitors for integrin-targeted cancer therapy | Q39063433 | ||
| Conjugates of modified cryptophycins and RGD-peptides enter target cells by endocytosis. | Q39198665 | ||
| Design, synthesis, and biological evaluation of novel cRGD-paclitaxel conjugates for integrin-assisted drug delivery. | Q39318537 | ||
| Direct fluorescence monitoring of the delivery and cellular uptake of a cancer-targeted RGD peptide-appended naphthalimide theragnostic prodrug | Q39340764 | ||
| Novel tumor-targeted RGD peptide-camptothecin conjugates: synthesis and biological evaluation | Q39770125 | ||
| Cilengitide: an RGD pentapeptide ανβ3 and ανβ5 integrin inhibitor in development for glioblastoma and other malignancies | Q39770397 | ||
| RGD peptide conjugation results in enhanced antitumor activity of PD0325901 against glioblastoma by both tumor-targeting delivery and combination therapy | Q39845706 | ||
| Tumor suppressor KAI1 affects integrin alphavbeta3-mediated ovarian cancer cell adhesion, motility, and proliferation | Q39860223 | ||
| In vitro and in vivo evaluation of doxorubicin conjugates with the divalent peptide E-[c(RGDfK)2] that targets integrin alphavbeta3. | Q39968412 | ||
| Integrin alphavbeta3 mediates upregulation of epidermal growth-factor receptor expression and activity in human ovarian cancer cells | Q39968522 | ||
| Activated epidermal growth factor receptor induces integrin alpha2 internalization via caveolae/raft-dependent endocytic pathway | Q40192630 | ||
| AlphaVbeta3 integrin regulates heregulin (HRG)-induced cell proliferation and survival in breast cancer. | Q40443936 | ||
| Synthesis and biological evaluation of dimeric RGD peptide-paclitaxel conjugate as a model for integrin-targeted drug delivery. | Q40457486 | ||
| Expression of integrin alphavbeta3 in gliomas correlates with tumor grade and is not restricted to tumor vasculature | Q41822458 | ||
| Conjugates of a Novel 7-Substituted Camptothecin with RGD-Peptides as αvβ3 Integrin Ligands: An Approach to Tumor-Targeted Therapy | Q42857513 | ||
| Development of a novel prodrug of paclitaxel that is cleaved by prostate-specific antigen: An in vitro and in vivo evaluation study | Q42864060 | ||
| Expression of integrin alphaVbeta3 in pancreatic carcinoma: relation to MMP-2 activation and lymph node metastasis. | Q44079888 | ||
| MicroPET imaging of breast cancer alphav-integrin expression with 64Cu-labeled dimeric RGD peptides | Q45068701 | ||
| Evaluation of biodistribution and anti-tumor effect of a dimeric RGD peptide-paclitaxel conjugate in mice with breast cancer | Q46676989 | ||
| Conjugation of resveratrol with RGD and KGD derivatives | Q46790786 | ||
| Paul Ehrlich's magic bullet concept: 100 years of progress | Q48322740 | ||
| Dual-drug RGD conjugates provide enhanced cytotoxicity to melanoma and non-small lung cancer cells. | Q50897550 | ||
| Plant Antitumor Agents. I. The Isolation and Structure of Camptothecin, a Novel Alkaloidal Leukemia and Tumor Inhibitor from Camptotheca acuminata1,2 | Q56864507 | ||
| Integrin traffic | Q57375293 | ||
| P433 | issue | 6 | |
| P304 | page(s) | 579-604 | |
| P577 | publication date | 2017-04-10 | |
| P1433 | published in | Future Medicinal Chemistry | Q19280078 |
| P1476 | title | RGD-mediated delivery of small-molecule drugs | |
| P478 | volume | 9 |
| Q92944926 | An RGD-Containing Peptide Derived from Wild Silkworm Silk Fibroin Promotes Cell Adhesion and Spreading |
| Q91643705 | Conjugates of Cryptophycin and RGD or isoDGR Peptidomimetics for Targeted Drug Delivery |
| Q57757467 | In Vivo Characterization of 4 Ga-Labeled Multimeric RGD Peptides to Image αβ Integrin Expression in 2 Human Tumor Xenograft Mouse Models |
| Q99587442 | Linker Hydrophilicity Modulates the Anticancer Activity of RGD-Cryptophycin Conjugates |
| Q64120193 | Mitochondria-specific drug release and reactive oxygen species burst induced by polyprodrug nanoreactors can enhance chemotherapy |
| Q47432742 | Novel c(RGDyK)-based conjugates of POPAM and 5-fluorouracil for integrin-targeted cancer therapy. |
| Q46507854 | RGD Peptide-Based Target Drug Delivery of Doxorubicin Nanomedicine. |
| Q33832735 | RGD-Binding Integrins in Head and Neck Cancers |
| Q93068998 | Size-Dependent Cellular Uptake of RGD Peptides |
| Q90212229 | Small-Format Drug Conjugates: A Viable Alternative to ADCs for Solid Tumours? |
| Q57973088 | Synthesis and Biological Evaluation of Paclitaxel Conjugates Involving Linkers Cleavable by Lysosomal Enzymes and αV β3 -Integrin Ligands for Tumor Targeting |
| Q92794475 | Synthesis and Biological Evaluation of RGD⁻Cryptophycin Conjugates for Targeted Drug Delivery |
| Q89910217 | The functions and applications of A7R in anti-angiogenic therapy, imaging and drug delivery systems |
| Q57975614 | Toward Angiogenesis Inhibitors Based on the Conjugation of Organometallic Platinum(II) Complexes to RGD Peptides |
Search more.